GlassScriptPhysician profile
Shannon Ethridge
NPI 1033527254
$2,731.32
in general payments reported to CMS, 2019-2025
36 companies · $738 in 2025
The $738 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $66.87 · 2022: $394 · 2023: $695 · 2024: $838 · 2025: $738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,203 · Education: $67.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,202.85 |
| Education | $67.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $644.89 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Astellas Pharma US INC | $223.49 | 2024-2025 | Veozah |
| Amgen INC. | $178.79 | 2022-2025 | Otezla, Repatha, Repatha |
| Otsuka America Pharmaceutical, INC. | $168.72 | 2023-2025 | Rexulti, Abilify Maintena |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $142.86 | 2022-2024 | Xifaxan, Trulance |
| Lilly USA, LLC | $132.45 | 2022-2024 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $123.47 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $119.30 | 2021-2023 | Farxiga |
| Noven Therapeutics, LLC | $115.11 | 2023-2024 | Xelstrym |
| Abbvie INC. | $87.06 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $87.00 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $78.06 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.72 | 2022-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $43.88 | 2024 | Spravato, Xarelto |
| Ironshore Pharmaceuticals INC. | $43.50 | 2023-2024 | Jornay Pm |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $39.36 | 2023-2024 | Ajovy, Austedo Xr |
| Baxter Healthcare | $38.71 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Shield Therapeutics INC | $35.63 | 2025 | |
| Phathom Pharmaceuticals, INC. | $34.22 | 2024 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $32.07 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $30.37 | 2021 | |
| Antares Pharma, INC. | $28.65 | 2022 | |
| Ascensia Diabetes Care US INC. | $27.58 | 2023 | |
| Vertex Pharmaceuticals Incorporated | $25.61 | 2025 | |
| Scilex Pharmaceuticals INC. | $22.29 | 2023 | Ztlido |
| Lundbeck LLC | $20.89 | 2025 | Rexulti |
| Alexion Pharmaceuticals, INC. | $19.80 | 2025 | Strensiq |
| Hologic Sales and Service, LLC | $18.80 | 2023 | Aptima |
| Verona Pharma, INC. | $18.77 | 2025 | Ohtuvayre |
| Corcept Therapeutics | $18.44 | 2025 | Korlym |
| Abbott Laboratories | $16.37 | 2025 | Freestyle Libre |
| Neos Therapeutics, LP | $14.54 | 2024 | Adzenys Xr-Odt |
| Ardelyx, INC. | $13.77 | 2025 | Ibsrela |
| Esperion Therapeutics, INC. | $13.74 | 2022 | |
| Glaxosmithkline, LLC. | $11.81 | 2022 | |
| Genentech USA, INC. | $8.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon Ethridge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.